MacroGenics, Inc.

MGNX Healthcare Biotechnology

In the quarter to June 2026, revenue grew 378.0%, EPS grew 154.4% and free cash flow grew 12.9%, each against the same quarter a year earlier.

3.25 0.12 −3.56%
Market cap
$214.7M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
3/9
Altman Z
−6.01
Beneish M
−0.22
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 3 3 2
ROE
(81.13%) (86.95%) (140.27%) (32.61%)
ROA
(28.36%) (28.78%) (31.80%) (4.94%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(37.64%) (41.70%) (71.74%) (6.78%)
Average Days of Receivables
225.11 1.04 24.22 287.49
Free Cash Flow per Share
(2.61) (1.31) (1.13) (1.03)
Free Cash Flow
(164.76) (82.94) (71.68) (65.53)
Other line items

Show all line items

Columns are period end dates